HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)

NCT07379190 | Not Yet Recruiting Phase 3 DMC

• 1 other identifier: TITAN
• Study Type: interventional
• Target: 458
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to address the existing clinical challenges by introducing high-resolution magnetic resonance vessel wall imaging (HR-MRI), an advanced imaging technology, to achieve precise etiological classification in patients with acute ischemic stroke (AIS) beyond the time window. HR-MRI allows clear visualization of intracranial arterial wall structures and direct identification of key pathological features of the culprit vessel, including atherosclerotic plaques, vascular wall remodeling, and intracranial hemorrhage, thereby enabling reliable differentiation between intracranial atherosclerotic large artery atherosclerosis (ICAS-LAA) stroke and other etiological subtypes such as cardiogenic embolism. Based on the latest clinical demands and advances in imaging technology, this study intends to evaluate the efficacy and safety of tirofiban in patients with ICAS-LAA stroke beyond the time window under the precise guidance of HR-MRI. It is expected to provide high-level evidence-based medical evidence for this specific patient population and further optimize clinical diagnosis and treatment strategies.

Conditions

Stroke, Acute; Stroke, Ischemic; Cerebral Infarction

Outcome Measures

Primary Outcomes (1)

• Proportion of participants with functional independence outcome [modified Rankin Scale(mRS) score 0-1]

  the mRs is an ordinal disability score of 7 categories (0=no symptoms to 5=severe disability,and 6=death); a lower score indicates a better prognosis.

  90 ± 7 days after randomization

Secondary Outcomes (15)

• Proportion of participants with good prognosis (mRS score 0-2)

  90 ± 7 days after randomization

• Proportion of participants with mRS score 0-3

  90 ± 7 days after randomization

• Distribution of mRS scores

  90 ± 7 days after randomization

• EuroQol Five-Dimension Questionnaire (EQ-5D) score

  90 ± 7 days after randomization

• Barthel Index (BI) score

  90 ± 7 days after randomization

Study Arms (2)

Tirofiban Combined with Standard Medication Therapy Group

EXPERIMENTAL

Patients were randomized to the Tirofiban Combined with Dual Antiplatelet Therapy Group. Intravenous tirofiban was administered within 30 minutes of randomization, with an initial bolus infusion at a rate of 0.4 μg/(kg·min) for 30 minutes, followed by a continuous infusion at 0.1 μg/(kg·min) for 47.5 hours. During this period, dual antiplatelet therapy (DAPT) was initiated at a dose of aspirin 100 mg/day plus clopidogrel 75 mg/day, with an overlapping duration of 4-6 hours. After the completion of tirofiban infusion, dual antiplatelet therapy (aspirin 100 mg/day plus clopidogrel 75 mg/day) was continued for a total of 21 days, followed by long-term maintenance with aspirin 100 mg/day alone.

Drug: Tirofiban; Drug: dual antiplatelet therapy

Standard Medication Therapy Group

ACTIVE COMPARATOR

Patients were randomized to the control group, with dual antiplatelet therapy (DAPT) initiated as early as possible at a dose of aspirin 100 mg/day plus clopidogrel 75 mg/day for a total of 21 days, followed by long-term maintenance with aspirin 100 mg/day alone.

Drug: dual antiplatelet therapy

Interventions

Tirofiban DRUG

Intravenous tirofiban was administered within 30 minutes of randomization, with an initial bolus infusion at a rate of 0.4 μg/(kg·min) for 30 minutes, followed by a continuous infusion at 0.1 μg/(kg·min) for 47.5 hours.

Tirofiban Combined with Standard Medication Therapy Group

dual antiplatelet therapy DRUG

Initiate dual antiplatelet therapy as early as possible (aspirin 100 mg/day plus clopidogrel 75 mg/day) for a total of 21 days, followed by long-term maintenance with aspirin 100 mg/day alone. For patients at high risk of stroke, such as those with severe stenosis of major blood vessels, dual antiplatelet therapy should be administered for 90 days.

Also known as: aspirin, clopidogrel

Standard Medication Therapy Group; Tirofiban Combined with Standard Medication Therapy Group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years old;
• Acute ischemic stroke (AIS) in the anterior intracranial circulation (internal carotid artery system) confirmed by clinical symptoms and imaging examinations;
• Time from symptom onset or last known normal state to randomization: \> 24 hours and ≤ 7 days;
• Stroke subtype confirmed as intracranial large artery atherosclerosis (ICAS) by high-resolution vessel wall imaging (HR-VWI) according to the TOAST classification, with cardiogenic embolism and other etiologies excluded;
• Baseline National Institutes of Health Stroke Scale (NIHSS) score of 4-20 at the time of randomization;
• Signed informed consent form obtained from the patient or their legal representative.

You may not qualify if:

• Planned to receive reperfusion therapy (endovascular therapy or intravenous thrombolysis)；
• Intracranial hemorrhage confirmed by computed tomography (CT)；
• Definite or suspected cardiogenic embolism；
• History of atrial fibrillation or current electrocardiogram indicating atrial fibrillation；
• Acute ischemic stroke caused by other etiologies, such as Moyamoya disease, arterial dissection, arteritis, etc；
• Imaging examinations indicating that the area of the current cerebral infarction exceeds 1/2 of the area of a single cerebral lobe;
• Known contraindications to antiplatelet therapy, including hematochezia, gastrointestinal bleeding, or any other hemorrhagic disorders;
• History of hypersensitivity to aspirin;
• Definite indication for anticoagulant therapy expected during the study period (e.g., atrial fibrillation, mechanical heart valve, deep vein thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state, etc.);
• Complicated with malignant tumors, chronic hemodialysis, severe renal insufficiency (glomerular filtration rate \[GFR\] \< 30 ml/min or serum creatinine \[Cr\] \> 220 μmol/L (2.5 mg/dl)), or severe hepatic insufficiency (serum alanine aminotransferase \[ALT\] \> 2 times the upper limit of normal \[ULN\], or serum aspartate aminotransferase \[AST\] \> 2 times the ULN);
• Severe heart failure (New York Heart Association \[NYHA\] Functional Classification Class III or IV);
• Complicated with severe non-cardiovascular comorbidities, with an estimated survival time \< 6 months;
• Concurrent new cerebral infarction in both anterior and posterior circulations;
• Inability to complete the follow-up procedures;
• Presence of other known neurological disorders that may complicate the follow-up;

Sponsors & Collaborators

• Weifang Medical University: lead
• Linyi People's Hospital: collaborator
• Qianfoshan Hospital: collaborator

Study Sites (1)

Weifang People's Hospital

Weifang, China/Shandong Province, 261000, China

Location

MeSH Terms

Conditions

Stroke; Ischemic Stroke; Cerebral Infarction

Interventions

Tirofiban; Aspirin; Clopidogrel

Condition Hierarchy (Ancestors)

Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Brain Infarction; Brain Ischemia; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis

Intervention Hierarchy (Ancestors)

Tyrosine; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids; Amino Acids, Peptides, and Proteins; Salicylates; Hydroxybenzoates; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Ticlopidine; Thienopyridines; Thiophenes; Sulfur Compounds; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Central Study Contacts

Weili Li, MD

CONTACT

86-0536-8192680; wfsrmyy_ky@163.com

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: January 22, 2026
• First Posted: January 30, 2026
• Study Start: February 1, 2026
• Primary Completion (Estimated): February 1, 2029
• Study Completion (Estimated): May 1, 2029
• Last Updated: February 4, 2026

Record last verified: 2026-01

Locations

CN (1)